Since the development of the first [64Cu]DOTA labeled antibody (IgG) PD-1 radiotracer by Natarajan et al. [63] in 2015, being tested on mice bearing B16-10 melanoma tumors, several immune checkpoint radiotracers have been developed both for SPECT and PET imaging. Here, PDCD1 is linked to melanoma.